Kristen L. Alexander - 28 Feb 2025 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
VP, Finance and Accounting
Signature
/s/ Kristen L. Alexander
Issuer symbol
LXRX
Transactions as of
28 Feb 2025
Net transactions value
-$11,968
Form type
4
Filing time
03 Mar 2025, 16:33:57 UTC
Previous filing
18 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +10,617 +22% 58,417 28 Feb 2025 Direct F1
transaction LXRX Common Stock Options Exercise +15,926 +27% 74,343 28 Feb 2025 Direct F1
transaction LXRX Common Stock Options Exercise +19,887 +27% 94,230 28 Feb 2025 Direct F1
transaction LXRX Common Stock Tax liability $11,968 -17,862 -19% $0.6700 76,368 28 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -10,617 -100% 0 28 Feb 2025 Common Stock 10,617 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -15,926 -50% 15,927 28 Feb 2025 Common Stock 15,926 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -19,887 -33% 39,773 28 Feb 2025 Common Stock 19,887 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.